ASP-4345

ASP-4345, or ASP4345, is a dopamine D₁ receptor positive allosteric modulator which is or was under development for the treatment of schizophrenia.^[1][4][5][3] It is being developed as an adjunctive therapy for the cognitive symptoms of schizophrenia.^[1] The drug is taken orally.^[1][2][3]

Other namesASP4345

Routes of
administrationOral^[1][2][3]

Drug classDopamine D₁ receptor positive allosteric modulator

ATC code

• None

Quick facts Clinical data, Other names ...

ASP-4345

Clinical data
Other names	ASP4345
Routes of administration	Oral[1][2][3]
Drug class	Dopamine D1 receptor positive allosteric modulator
ATC code	None
Pharmacokinetic data
Elimination half-life	9.1–26.8 hours[3]
Identifiers
IUPAC name 2-(5-chloro-2-oxo-1,3-benzoxazol-3-yl)-N-methyl-N-[[6-(trifluoromethyl)-1H-benzimidazol-2-yl]methyl]acetamide
CAS Number	1632257-75-0 Y
PubChem CID	85470885
ChemSpider	128727345
UNII	JT5NU1K4F2
ChEMBL	ChEMBL4558647
Chemical and physical data
Formula	C19H14ClF3N4O3
Molar mass	438.79 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN(CC1=NC2=C(N1)C=C(C=C2)C(F)(F)F)C(=O)CN3C4=C(C=CC(=C4)Cl)OC3=O
InChI InChI=1S/C19H14ClF3N4O3/c1-26(8-16-24-12-4-2-10(19(21,22)23)6-13(12)25-16)17(28)9-27-14-7-11(20)3-5-15(14)30-18(27)29/h2-7H,8-9H2,1H3,(H,24,25) Key:YJODOMNPYLHYJK-UHFFFAOYSA-N

Close

The most common side effects of ASP-4345 have been found to be headache and somnolence.^[2] No changes in mood or suicidality were observed.^[2] The pharmacokinetics of ASP-4345 have been studied.^[3] The median time to peak levels of ASP-4345 is 1.0 to 3.0 hours.^[3] Its mean elimination half-life is 9.1 to 26.8 hours.^[3]

ASP-4345 is or was under development by Astellas Pharma.^[1][4] As of March 2021, no recent development has been reported.^[1] The drug has reached phase 2 clinical trials for schizophrenia.^[1][4] It was found to be ineffective in a phase 2 trial.^[5]